Mr Erik Bergman is the CFO at Senzime. He has over 30 years´ experience from small and medium-sized, listed or private, Life Science companies such as Novavax, Orexo and Phadia (presently Thermo Fisher Scientific). Experience includes financial reporting to the stock market and raising of capital, IPOs and M&As, as well as internal financial control and business development. Previous positions includes roles as CFO and CEO. Erik holds a B.Sc. in Business Administration and Economics from Uppsala University.
Member of the Senzime Management Team since 2019.
Erik Bergman holds 5 000 shares.